Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study

Frontiers in Nutrition, Год журнала: 2025, Номер 12

Опубликована: Апрель 25, 2025

Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrient intake while using a GLP-1RA. The purpose of this study was to compare GLP-1RA the Dietary Reference Intakes (DRI). A cross-sectional conducted in sample participants who had been at least one month (N = 69). Participants answered online survey questionnaires and completed 3-day food record. Descriptive statistics (means, standard deviations) were calculated all participant demographic characteristics average intakes. Average intakes compared DRI 95% confidence intervals (CI). Bonferroni correction applied accepted significance p ≤ 0.00156. One-way ANOVA analysis self-reported MyPlate servings recorded from Compared reference values, consumed adequate amounts B-vitamins, copper, phosphorus, selenium, zinc. insufficient several key nutrients below DRI, including fiber (14.5 g; CI: 12-17), calcium (863 mg; 756-970), iron (12.1 11-13), magnesium (266 236-297), potassium (2,186 1,969-2,402), choline (305 268-342), vitamin (560 mcg RAE; 469-651), C (51 41-61), D (4 mcg; 3-5), E (9.6 8-11), < overconsumed % calories fat (39.9%; 38, 42), saturated (26 26, 26), did not meet daily recommended fruit, vegetables, grains, or dairy (p 0.01). Protein (% total calories) within AMDR, however based on g/kg/day, protein significantly under needs. are meeting vital through their diet higher needs during weight loss. Patient-centered nutritional guidance essential optimize health outcomes prevent unintended consequences. Future large-scale studies needed assess replicability these findings provide custom those medication.

Язык: Английский

---

Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects

Obesities, Год журнала: 2025, Номер 5(2), С. 29 - 29

Опубликована: Апрель 24, 2025

Background/Objectives: Obesity is a chronic, progressive, recurrent disease associated with impaired health, affecting an increasing proportion of the population worldwide. Newer-generation incretin-based therapies (IBTs) (liraglutide, semaglutide, and tirzepatide) have shown greater efficacy than older anti-obesity medications. This systematic literature review provides overview evidence on symptomatic adverse events (AEs) patient-reported outcomes IBTs to facilitate clinical decision-making. Methods: A search was conducted using predefined strategy identify controlled trials real-world (RWE) studies assessing IBTs. Results: Among 4414 publications identified, 81 (>400,000 participants) were included. Liraglutide (n = 49), semaglutide 34), tirzepatide 7) used in 48 33 RWE studies. Gastrointestinal (GI) AEs most common: placebo-subtracted incidences 5–39% for nausea, −7–39% diarrhea, 2–31% constipation, 0–26% vomiting, 2–20% abdominal pain, no clear difference across Most mild or moderate mainly occurred during dose escalation. Quality life reported 27 generally showed improvements Conclusions: study confirms that GI are common Clinicians should keep AE profile mind consider where additional preventative measures may be required.

Язык: Английский

---

What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?

Current Obesity Reports, Год журнала: 2025, Номер 14(1)

Опубликована: Май 7, 2025

Язык: Английский

---

Optimising nutrition: a cornerstone of health and longevity

South African General Practitioner, Год журнала: 2024, Номер 5(4), С. 165 - 169

Опубликована: Ноя. 1, 2024

Язык: Английский

---